賽隆藥業(002898.SZ):“阿加曲班注射液”、“注射用胸腺法新”處於“審批完畢-待制證”狀態 “注射用替加環素”處於“制證完畢-待發批件”狀態
格隆匯12月19日丨賽隆藥業(002898.SZ)公佈,近日,經查詢國家藥品監督管理局網站(“國家藥監局”)獲悉:公司全資子公司湖南賽隆藥業有限公司向國家藥監局提交的“阿加曲班注射液”、“注射用胸腺法新”國產藥品註冊申請處於“審批完畢-待制證”狀態;“注射用替加環素”國產藥品註冊申請處於“制證完畢-待發批件”狀態。
“審批完畢-待制證”表示國家藥監局行政事項受理服務和投訴舉報中心已經審批完畢正在製作批件;“制證完畢-待發批件”表示國家藥監局行政事項受理服務和投訴舉報中心批件製作結束待送達。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.